Views on Chinese medicines sought

March 31, 2021

The Department of Health today launched a six-month public consultation on the amendments to the limits for harmful residues in Chinese herbal medicines in Hong Kong proposed by the Chinese Medicines Board under the Chinese Medicine Council of Hong Kong.

 

The council, a statutory body established under the Chinese Medicine Ordinance, is responsible for implementing regulatory measures for Chinese medicine practitioners and Chinese medicines, including setting limits for harmful residues in Chinese herbal medicines.

 

As the relevant standards published in the Pharmacopoeia of the People's Republic of China (2020 Edition) have come into effect on December 2020, the board has set up a working group to comprehensively review and advise on the limits of harmful residues in Chinese herbal medicines in Hong Kong, including aflatoxins, heavy metals and toxic elements and pesticide residues, and the related measures for implementation.

 

Upon deliberation, the working group composed of representatives and experts of the Chinese medicines trade as well as representatives of the testing industry, proposed a series of amendments, consultation and related measures for implementation in phases.

 

Members of the Chinese medicines trade and the public can express their views by post to 16/F, AIA Kowloon Tower, Landmark East, 100 How Ming Street, Kwun Tong, Kowloon, fax to 2319 2664 or email at safetylimit@cmchk.org.hk or safetylimit@dh.gov.hk on or before September 30.

Back to top